Ceci Adriana, Mangiarini Laura, Felisi Mariagrazia, Bartoloni Franco, Ciancio Angela, Capra Marcello, D'Ascola Domenico, Cianciulli Paolo, Filosa Aldo
Consorzio per Valutazioni Biologiche e Farmacologiche, Via L. Porta 14, 27100 Pavia, Italy.
Anemia. 2011;2011:435683. doi: 10.1155/2011/435683. Epub 2011 Jun 5.
Thalassaemia and other haemoglobinopathies constitute an important health problem in Mediterranean countries, placing a tremendous emotional, psychological, and economic burden on their National Health systems. The development of new chelators in the most recent years had a major impact on the treatment of thalassaemia and on the quality of life of thalassaemic patients. A new initiative was promoted by the Italian Ministry of Health, establishing a Registry for thalassaemic patients to serve as a tool for the development of cost-effective diagnostic and therapeutic approaches and for the definition of guidelines supporting the most appropriate management of the iron-chelating therapy and a correct use of the available iron-chelating agents. This study represents the analysis of the preliminary data collected for the evaluation of current status of the iron chelation practice in the Italian thalassaemic population and describes how therapeutic interventions can widely differ in the different patients' age groups.
地中海贫血和其他血红蛋白病在地中海国家构成了一个重要的健康问题，给其国家卫生系统带来了巨大的情感、心理和经济负担。近年来新型螯合剂的开发对地中海贫血的治疗以及地中海贫血患者的生活质量产生了重大影响。意大利卫生部发起了一项新倡议，建立了地中海贫血患者登记处，作为制定具有成本效益的诊断和治疗方法以及确定支持铁螯合疗法最适当管理和正确使用现有铁螯合剂的指南的工具。本研究分析了为评估意大利地中海贫血人群铁螯合治疗现状而收集的初步数据，并描述了不同年龄组患者的治疗干预措施如何存在广泛差异。
